Leerink analyst David Larsen remains positive on CVS Health following earnings. The analyst believes the stock has come under "significant pressure" due to negative sentiment around transparency, Trump, DIR fees, the loss of volumes to WBA, pricing, and the new threat of Optum. However, Larsen expects sentiment to turn-around in 2017 as pricing is now fully accounted for in CVS' outlook, Trump will discover that the PBMs improve net drug trend, and PBM is having a good selling season with a high retention rate and good new wins. He reiterates an Outperform rating and $90 price target on the shares.